Ps1417 Treatment Outcomes of Patients With Monoclonal Gammopathy of Clinical Significance

Abstract

Methods:We reviewed the clinical records of MM patients diagnosed at a single institution between 1970 and 2015. One thousand one hundred sixty-one patients (591 [50.9%] male; median age at diagnosis 64 years) was the final study population. Median follow-up for alive patients was 5.4 years (range, 0.5-34.4 years). Relative survival (RS) and disease-specific incidence mortality were calculated and expressed in incidence rate ratio (IRR). Long-term survival was defined as those who lived more than 10 years after diagnosis of MM. The population was divided into three periods, which included: group A (1970 to 1985), group B (1986 to 1999) and group C (2000 to 2015). Results: The median OS (mOS) of all patients was 3.6 years (95% CI: 3.2-3.8) from diagnosis. When demographic effects of age, sex, and year of diagnosis were compensated, the RS showed a continuous improvement during the periods analyzed, more pronounced in group C. The 5-year and 10-year RS were 26% and 8% in group A, 36% and 18% in group B, and 56% and 33% in group C, p < 0.01. In the stratified analysis by age and sex, group B and C retained its prognostic value in terms of IRR compared with group A (Figure 1). The EM rate (first 60 days after diagnosis) was 5.8%; 16.5% in Group A, 5.5% in Group B, and 2.6% in Group C; p < 0.01. The most frequent causes of early mortality were disease-related (46.7%, 63.6% and 66.6%; respectively), and infectious complications (36.7%, 22.7%, and 20.0%; respectively). In the multivariate Cox proportional hazard model in patients who received novel drugs, thrombocytopenia (OR 5.07, p = 0.04), hypercalcemia (OR 11.5, p < 0.01) and high beta-2 microglobulin (OR 8.81, p < 0.01) were significantly associated with EM. Regarding long-term survival, in the multivariate analysis, clinical variables at diagnosis associated with >10-year survival were age <60 years (OR 2.23, p = 0.02), and performing ASCT (OR 4.25, p < 0.01). Summary/Conclusion:This study shows that the survival outcome has significantly improved over the last decades in all age groups, probably due to ASCT and novel drugs. The incidence of EM has decreased over time, being the most frequent causes of MM progression and infectious complications. Thrombocytopenia, hypercalcemia and high beta-2 microglobulin were associated with worst early outcomes. Finally, these data identify age <60 years, and ASCT as important predictors of longterm survival.

Highlights of the 24th European Hematology Association Congress, Amsterdam 2019

“…The results of treatment performed in 151 patients with monoclonal gammopathy of clinical significance (MGCS) at Raisa Gorbacheva Memorial Institute were also presented by Kudyasheva et al [22]. Kidney, heart, liver, nervous system and gastrointestinal tract were the most commonly involved organs here.…”

“…The overall survival in patients with CR was 100%; VGPR, 88.4%; PR,95%; the patients that did not achieve renal response comprised 58.3% (p=0.0031). The 5-year renal PFS in the patients who achieved renal response was 70.9% [22].…”